Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Wolf

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Cell Reports|February 28, 2025
Custom affinity probes reveal DNA-damage-induced, ssDNA-independent chromatin SUMOylation in budding yeastVera Tröster, Ronald P Wong, Arne Börgel, et al.
Intervirology|January 31, 2012
HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledgeMartin Obermeier, Alejandro Pironti, Thomas Berg, et al.
British Journal of Haematology|May 15, 2004
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's diseaseChristian Hoffmann, Kai Uwe Chow, Eva Wolf, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2022
Two light sensors decode moonlight versus sunlight to adjust a plastic circadian/circalunidian clock to moon phaseMartin Zurl, Birgit Poehn, Dirk Rieger, et al.
Open Forum Infectious Diseases|July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered QuestionsAnna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
AIDS (London, England)|September 22, 2006
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionGuenther Schmutz, Mark Nelson, Thomas Lutz, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 27, 2010
Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification testsJoachim Glaubitz, Dorothea Sizmann, Christian O Simon, et al.
HIV Research & Clinical Practice|March 2, 2022
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changesMalte Monin, Tim Kümmerle, Jochen Schneider, et al.
AIDS Care|April 26, 2021
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-studyElisabeth Olliges, Bernhard Bührlen, Franz Fischer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2010
Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognitionSandra M Mueller, Bernd M Spriewald, Silke Bergmann, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Cell Reports|February 28, 2025
Custom affinity probes reveal DNA-damage-induced, ssDNA-independent chromatin SUMOylation in budding yeastVera Tröster, Ronald P Wong, Arne Börgel, et al.
Intervirology|January 31, 2012
HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledgeMartin Obermeier, Alejandro Pironti, Thomas Berg, et al.
British Journal of Haematology|May 15, 2004
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's diseaseChristian Hoffmann, Kai Uwe Chow, Eva Wolf, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2022
Two light sensors decode moonlight versus sunlight to adjust a plastic circadian/circalunidian clock to moon phaseMartin Zurl, Birgit Poehn, Dirk Rieger, et al.
Open Forum Infectious Diseases|July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered QuestionsAnna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
AIDS (London, England)|September 22, 2006
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionGuenther Schmutz, Mark Nelson, Thomas Lutz, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 27, 2010
Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification testsJoachim Glaubitz, Dorothea Sizmann, Christian O Simon, et al.
HIV Research & Clinical Practice|March 2, 2022
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changesMalte Monin, Tim Kümmerle, Jochen Schneider, et al.
AIDS Care|April 26, 2021
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-studyElisabeth Olliges, Bernhard Bührlen, Franz Fischer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2010
Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognitionSandra M Mueller, Bernd M Spriewald, Silke Bergmann, et al.
Pageof 13